Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 24% of the time (231 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-07-06. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancercell lungsmall cellnon smallcarboplatin
  Phrases that lowered it: participantssolidlenalidomideevaluate theto evaluate
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 10.7% (raises risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 33.2% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 300 (raises risk) · Sponsor's track record
• Sponsor's past trials: 535 (lowers risk) · Sponsor's track record
• Sponsor type: government (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Keywords listed: 10 (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Maximum age: not given (raises risk) · Who can join
• Design: sequential (raises risk) · Design
• Disease area, urogenital: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: 92.7% (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 35071 (raises risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma NCT01342172 · started 2011 · scored riskier than 93% of active trials terminated
• Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer NCT00903630 · started 2009 · scored riskier than 93% of active trials terminated
• Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer NCT01254617 · started 2011 · scored riskier than 91% of active trials completed
• A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse NCT01111903 · started 2009 · scored riskier than 78% of active trials completed
• A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma NCT04501094 · started 2020 · scored riskier than 91% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.